In 2014, Kulkarni et al. showed that blocking TLR4 at the early stage of injury can prevent the progression of ATN and AKI, but blocking TLR4 at the recovery stage can inhibit IL-22 production and damage renal regeneration [57]. The gene discussed is TLR4; the disease is oculocutaneous albinism type 1.